腹腔镜下胃空肠分流术（RRYGB）被认为是高发胃癌国家的一种替代性减重手术，因为RRYGB后没有排除胃。本研究旨在评估RRYGB的疗效和安全性。本研究纳入了2011年至2021年间接受RRYGB和袖式胃切除术（SG）的患者。患者术前和手术后1、6和12个月进行了手术并发症、代谢和营养状况的比较。其中，20例接受了RRYGB手术，76例接受了SG手术。SG组中有7例在1年内失访。两组的手术并发症和基线特征相似，除了糖尿病（90.0％对44.7％，p <0.001）。 RR RYGB组的HbA1c水平降低和反流性食道炎的发生率在术后1年时均低于SG组（-3.0％对-1.8％，p = 0.014；0％对26.7％，p = 0.027）。两组在术后1年的总体重减轻百分比和倾泻综合征发生率相似。 RR RYGB组在术后1年时总胆固醇水平显著降低（161.9毫克/分升对196.4毫克/分升，p <0.001），但维生素B12缺乏症的发生率更高（30.0％对3.6％，p = 0.003）。与SG组相比，RRYGB组在未增加手术并发症的情况下，糖尿病和血脂异常的术后疗效更好。因此，RRYGB可以被认为是胃癌高发地区的一种安全而有效的替代方法。 ©2023作者，独家许可Springer Science+Business Media, LLC，属于Springer Nature。

Resectional Roux-en-Y gastric bypass (RRYGB) is considered an alternative bariatric surgery in countries with a high incidence of stomach cancer because there is no excluded stomach after RRYGB. This study aimed to evaluate the efficacy and safety of RRYGB.This study included patients who underwent RRYGB and sleeve gastrectomy (SG) between 2011 and 2021. Surgical complications and metabolic and nutritional profiles were compared between the patients preoperatively and at 1, 6, and 12 months after surgery.Twenty and seventy-six patients underwent RRYGB and SG, respectively; 7 in the SG group were lost to follow-up within 1 year. Surgical complications and baseline characteristics were comparable between two groups, except for diabetes (90.0% vs. 44.7%, p < 0.001). The decrease of HbA1c levels and incidence of reflux esophagitis were lower in the RRYGB group compared to that of SG at 1-year postoperative (-3.0% vs. -1.8%, p = 0.014; 0% vs. 26.7%, p = 0.027). The percentage of total weight loss at 1- year postoperative and incidence of dumping syndrome were comparable between the two groups. The RRYGB group had significantly lower total cholesterol level (161.9 mg/dl vs. 196.4 mg/dl, p < 0.001), but higher incidence of vitamin B12 deficiency (30.0% vs. 3.6%, p = 0.003) at 1 year postoperative compared to those of the SG group.The RRYGB group had better postoperative outcomes for diabetes and dyslipidemia without increasing surgical complications compared to that of the SG group. Thus, RRYGB can be considered a safe and effective alternative in areas where gastric cancer is prevalent.© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.